Published in Nature reviews gastroenterology & hepatology
Recent technological advancements have provided unprecedented insights into the inflammatory mechanisms underlying liver fibrosis, leading to the identification of promising novel targets for anti-inflammatory and antifibrotic therapies.
Published in Journal of Hepatology (November 2023)
Peroxisome proliferated-activated receptors (PPARs), including α, β/δ and γ isotypes, are a nuclear receptor family of lipid sensors activated by natural fatty acid derivatives and pharmacological agonists.
Non-alcoholic fatty liver disease (NAFLD) can be categorised into two disease sub-classifications: non-alcoholic fatty liver (NAFL), its non-progressive subtype, and non-alcoholic steatohepatitis (NASH), its progressive form.
The last decade has seen an unprecedented amount of data in the way of therapeutic research for non-alcoholic steatohepatitis (NASH), the progressive form of non-alcoholic fatty liver disease (NAFLD).
Generally, NASH and fibrosis correlate with the development of cirrhosis and other negative clinical outcomes. Treatments often aim to target inflammation, fibrosis, cell injury or metabolic dysregulation.
Although it is known that non-alcoholic steatohepatitis (NASH) increases the risk of end-stage liver diseases such as cirrhosis and hepatocellular carcinoma, no pharmacologic therapy has yet been approved to treat it.
Authors: Stojsavljevic-Shapeski S, Duvnjak M, Virovic-Jukic L, et al.
Published in J Clin Transl Hepatol 2021
Extensive research and revelation in the field of pathogenesis of NASH has offered new possibilities of treatment and emerging new drugs that are being tested currently in numerous preclinical and clinical trials. These drugs target almost all steps in the pathogenesis of NASH...
This review by SL Attia et al. (University of Kentucky College of Medicine, USA) summarises emerging pharmacotherapies for the treatment of adult and paediatric NAFLD. Investigated pharmacotherapies include lanifibranor (IVA337), an indole sulfonamide PPAR agonist that activates....
Authors: Fougerat A, Montagner A, Loiseau N, et al
Published in Cells 202
The prevalence of NAFLD is dramatically increasing in developed countries, but no approved therapy is available. Most of the current pharmacological strategies target comorbidities, such as manifestations of metabolic syndrome. In addition, none of used medications improve fibrosis, which is the strongest indicator of mortality in NAFLD...
Progress in uncovering pathogenic determinants of fibrosis in NASH include metabolic dysregulation in hepatocytes that induce inflammation and cytokine secretion leading to cell injury and apoptosis, among others.This review by T. M. Huisman et al. (Division of Liver Diseases, Icahn School of Medicine at Mount Sinai...
Authors: Petroni ML, Brodosi L, Bugianesi E, et al.
Published in BMJ 2021
As explained in the review by M. L. Petroni et al. (“Alma Mater” University, Bologna, Italy), several drugs are under investigation according to the agreed targets of reduced NASH activity without worsening of fibrosis or improving fibrosis without worsening of NASH.
Anti-inflammatory, anti-fibrotic agents and metabolism modulators...
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES
Manage your privacy
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
